Antibiotics Market

Global Antibiotics Market - Distribution by Type of Drug Class, Target Disease Indication, Type of Therapy (Monotherapies and Combination Therapies), Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    191

  • Slides
    175

  • View Count
    11184

Antibiotics Market Overview

The global antibiotics market was estimated to be worth USD 36 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 1.2% during the forecast period. Bacterial infections are known to be one of the leading causes of deaths, worldwide. In fact, infections caused by bacteria are responsible for every one out of eight deaths, globally. This can be attributed to the fact that majority of the pathogenic bacteria have developed resistance against the commonly prescribed therapies. In addition, as per the Centers for Disease Control and Prevention (CDC), the annual healthcare cost associated with treatment of infections caused by six multi -drug resistant bacteria is estimated to be more than USD 4.6 billion in the US. Antibiotics (chemical substances derived from the biological sources or produced chemically), also known as antibacterial drugs, are extensively being used for the prevention / treatment of various bacterial infections. Over the past few years, a number of novel broad -spectrum antibiotics (antibiotics that provide therapeutic effects against a wide range of bacteria) and narrow spectrum antibiotics (antibiotics that provide therapeutic effects against specific bacterial strains only), targeting a myriad of bacterial infections (in alphabetical order), including anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis, have received approval from various regulatory authorities, globally. However, the antibiotic drug development is currently fraught with several challenges, including emergence of multi drug -resistant bacteria, antibiotics shortage (particularly penicillin shortage and amoxicillin shortage) and concerns related to safety and efficacy of these therapies. 

In order to address the aforementioned concerns, several industry stakeholders have been actively leading the efforts for research and development of effective and safe antibiotics. In addition, over the years, several regulatory organizations, including the World Health Organization (WHO), CDC and United States Food and Drug Administration (USFDA) have undertaken various initiatives to not only promote the correct usage of antibiotics but also support the players engaged in this industry. Driven by the continuous efforts of both industry and non-industry players and growing concerns associated with antimicrobial resistance, the global antibiotics market / global antibacterial drugs market is likely to witness significant growth during the forecast period.

This image provides list of approved. antibiotics. Presently, around 60 players worldwide are engaged in the development of novel antibiotics to treat a wide range of clinical conditions; majority of such players are headquartered in North America The infographic provides landscape of approved antibiotics. Close to 70% of the antibiotics have been approved for use in North America, specifically the US; majority of these therapies are quinolones approved for the prevention / treatment of pulmonary infections The image provides pipeline of clinical stage antibiotics. Currently, 150 clinical-stage antibiotics are being evaluated across different stages of preclinical / clinical development and different antibiotic classes, either as monotherapies or in combination with other drugs to target various types of bacteria

Key Market Insights

The Global Antibiotics Market - Distribution by Type of Drug Class (Aminoglycosides, Cephalosporins, Fluoroquinolones, Macrolides, Oxazolidinones, Penicillins, Sulphonamides, Tetracyclines and Other Drug Classes), Target Disease Indication (Bacterial Infections, Skin Infections, Gastrointestinal Infections, Hematological Infections, Nephrological Infections, Pulmonary Infections, Reproductive Tract Infections, Respiratory Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infections and Other Bacterial Infections), Type of Therapy (Monotherapies and Combination Therapies), Route of Administration (Intravenous and Oral), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), and Drug-wise Sales: Industry Trends and Global Forecasts, 2023-2035 market report features an extensive study of the current market landscape, market size and future opportunities for the antibiotics companies developing the antibacterial drugs, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the antibiotics market are briefly discussed below.

Need for Novel Antibacterial Drugs Targeting Multi -Drug Resistant Bacteria

Over the years, due to overuse of antibiotics, bacterial strains have developed resistance to most of the commercially available antibiotics, a phenomenon known as antibiotic resistance / antimicrobial resistance. Notably, in November 2021, the World Health Organization (WHO) declared antimicrobial resistance as one of the top ten threats for the global public health standards. In order to address the aforementioned challenge, pharmaceutical companies are currently evaluating various novel antibiotics. These novel antibiotics belong to previously unexplored drug classes that can target new pathways to inhibit bacterial growth. In addition, some of these therapies are being evaluated to overcome the challenges of cross resistance (commonly observed in currently available antibiotics).

Pipeline Analysis: Competitive Landscape of Antibiotics

Since 1980, multiple antibiotics have been approved for the prevention / treatment of various infection diseases,including urinary tract infection and skin infection, caused by gram negative as well as gram positive bacteria. Further, in the last eight years, developers have received approvals for more than 25 novel antibiotics intended for the treatment of multiple infectious diseases. It is worth highlighting that over 150 antibiotics are currently being evaluated in different stages of preclinical / clinical development, either as monotherapies or combination therapies. Majority of these clinical-stage antibiotics are being developed for the treatment of infections caused by members of Enterobacteriaceae family. The growing numbers of multi drug resistant bacteria and a rich pipeline of antibiotics targeting various infectious disease is expected to drive the antibiotics market growth during the forecast period.

Clinical Trials Analysis: More than to 1,720 Trials are Evaluating Various Antibiotic Drug Classes to Fight Antimicrobial Resistance

Over the years, companies involved in the development of antibiotics have made significant efforts to conduct clinical trials for evaluating the efficacy of antibiotics, for the treatment of various infectious diseases, including urinary tract infection, pulmonary infection, respiratory tract infection, sexually transmitted disease and skin infection. Currently, over 1,720 trials are registered across different geographical regions to evaluate various antibiotics drug classes. Of these trials, majority (696) were registered in North America. Within this region, the maximum number of trials were / are being conducted in the US (630). Additionally, majority of the patients (14,21,308) were observed to be enrolled in trials conducted in North America, accounting for about 20% of the overall enrollment. It is worth noting that Pfizer, GlaxoSmithKline, Merck, Melinta Therapeutics and Janssen emerged to be the most active companies in terms of number of clinical trials conducted in antibiotics market.

Market Trends Analysis: Partnership and Collaboration in Antibiotics Market

Currently, several partnerships have been inked by various industry and non-industry players engaged in the development of antibiotics. It is worth highlighting that 30% of these partnerships were inked in 2022. Majority of such deals are focused on joint development of antibiotics, followed by agreements signed for the purpose of research and development, product development and commercialization of antibiotics. In October 2022, Merck entered into an agreement with the Bill & Melinda Gates Medical Research Institute to license its two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis. 

Key Drivers for  Antibiotics Market Growth: COVID-19 Use, Emergence of Multi Drug Resistant Bacteria and Novel Antibiotics

It is worth highlighting that a significant surge has been observed in the use of antibiotics, since 2020. This can be attributed to the fact that various antibiotic generics, namely azithromycin, ceftriaxone, moxifloxacin and meropenem, were used extensively in the initial phase of the pandemic. However, the COVID-19 pandemic caused the disruption of the supply chain of antibiotics. Hence, in order to address the increasing demand as well as overcome the aforementioned supply chain-related disruption, a number of developers based in North America and Europe either expanded their facilities or established new facilities for the manufacturing of antibiotics.

The increasing prevalence of various infections caused by both gram positive and gram-negative bacteria is one of the key drivers for the antibiotics market. In addition, emergence of multi-drug resistant bacteria, current unmet need for novel antibiotics and extensive research and development initiatives by industry players are expected to drive the antibiotics market growth in the forecast period. In June 2023, Pfizer announced positive results from a phase III clinical trial of a novel antibiotic combination targeting multi drug resistant bacterial infections. The novel Aztreonam-Avibactam (ATM-AVI) combination is being jointly developed with AbbVie. These factors will drive the market growth for the antibiotics market during the forecast period.

Market Analysis: Global Antibiotics Market Size

The global antibiotics market is estimated to be worth USD 36 billion in 2023. Driven by the increasing need for novel antibiotics, along with growing development pipeline and encouraging clinical trial results, the antibiotics market is anticipated to grow at a CAGR of 1.2% during the forecast period. Specifically, in terms of target disease indication, the market is anticipated to be driven by antibacterial drugs being developed for the treatment of urinary tract infection, and skin infection. Additionally, it is worth highlighting that majority of the current market share is captured by players based in North America.

This image provides details on lanscape of clinical stage antibacterial drugs market. Given the rising prevalence of bacterial infections, over 50 stakeholders are focused on the development and evaluation of antibiotics targeting a wide range of gram positive and negative bacterial strains The infographic provides a view on the partnerships landscape in antibacterial drugs market. The growing interest in this domain is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to antibiotics have been inked in the last three years The image highlights market forecast of antibiotics market. The global antibiotics market is anticipated to grow at a steady pace in coming decade; majority of the share is captured by drugs targeting urinary tract infections

Leading Antibiotics Companies

Examples of the key players in this industry (the complete list of players is available in the full report) include ABAC Therapeutics, Bayer, Biocidium Biopharmaceuticals, Blacksmith Medicines, Bristol Myers Squibb, Crestone, Daiichi Sankyo, Debiopharm, Fedora Pharmaceuticals, Fujisawa Pharmaceutical, GlaxoSmithKline, Helperby Therapeutics, Madam Therapeutics, Melinta Therapeutics, Meiji Seika Pharma, MicuRx Pharmaceuticals, Merck, Pfizer, Qpex Biopharma, RedHill Biopharma, Selmod, Sequella, Sinovent, Spero Therapeutics and Wockhardt. The market report includes an easily searchable excel database of all the companies developing antibiotics worldwide.

Recent Developments in Antibiotic Market

Several recent developments have taken place in the field of antibiotics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, Bugworks Research collaborated with the Global Antibiotic Research and Development Partnership in order to accelerate the development of an antibiotic compound for the treatment of serious infections caused by multidrug-resistant bacteria. 
  • In April 2023, Pattern Bioscience secures USD 28.7 million in Series C funding round. 
  • In May 2023, Melinta Therapeutics entered into a commercialization and licensing agreement with Xediton Pharmaceuticals with the aim to launch BAXDELA®, KIMYRSA®, ORBACTIV® and VABOMERE® in Canada.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in theis antibiotics market / antibacterial drugs market, across different segments, as defined in the below table:

Key Report Attributes Details

Base Year

2023

Forecast Period

2023-2035

Market size

$36 Billion

CAGR

1.2%

Type of Drug Class

  • Aminoglycosides
  • Cephalosporins
  • Fluoroquinolones
  • Macrolides
  • Oxazolidinones
  • Penicillins
  • Sulphonamides
  • Tetracyclines
  • Other Drug Classes

Target Disease Indication

  • Bacterial Infections
  • Dermatological Infections
  • Gastrointestinal Infections
  • Hematological Infections
  • Nephrological Infections
  • Pulmonary Infections
  • Reproductive Tract Infections
  • Respiratory Tract Infections
  • Sexually Transmitted Diseases
  • Urinary Tract Infections
  • Other Bacterial Infections

Type of Therapy

  • Monotherapies
  • Combination therapies

Route of Administration

  • Intravenous
  • Oral

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Key Companies Profiled

  • Bristol Myers Squibb
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Melinta Therapeutics
  • Merck
  • Pfizer
  • (Full list of 190+ companies captured available in the report)

Customization Scope

  • 15% Free Customization Option (equivalent to 5 analyst working days)

Excel Data Packs (Complimentary)

  • Approved Antibiotic Generics Market Landscape
  • Approved Antibiotic Brands Market Landscape
  • Clinical-stage Antibiotics Market Landscape
  • Partnership and Collaboration Analysis
  • Clinical Trials Analysis
  • KOL Analysis
  • Success Protocol Analysis
  • Market Forecast and Opportunity Analysis

 

This image provides antibiotics market growth. The opportunity associated with the global antibiotics market is likely to be well distributed across various types of therapies, routes of administration and key geographical regions This image shares insights from key opinion leaders in antibiotics market. Several researchers from the renowned universities, currently involved in evaluating efficacy and safety of antibiotics, have emerged as key opinion leaders (KOL); of these, majority of the KOLs are doctors of medicine The infographics shares a success protocol analysis for antibiotics. Our proprietary analysis highlights the impact of more than 10 leading factors that must be taken into consideration for the development of an antibiotic

The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this market, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research, offering a high-level view on the current state of the global antibiotics market and its likely evolution in the mid-to-long term.
  • A general introduction to antibiotics/ antibacterial drugs, along with information on their characteristics and advantages, and classification (based on chemical structure, mode of action, range of activity and source). In addition, the chapter highlights details on the history of antibiotics, innovations related to antibiotics, mechanism of action of antibiotics and challenges associated with their use. Further, it concludes with a discussion on the future perspectives in this industry.
  • A detailed assessment of the overall market landscape of approved antibiotic generics, based on several relevant parameters, such as year of approval, region(s) of approval, type of antibiotic (based on chemical structure and drug class), mechanism of action (alteration of cell membranes, cell wall synthesis inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and RNA polymerase inhibition), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria(s) (gram negative and gram positive), target bacterial strain(s), target diseases indication(s), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral, topical and others / unspecified), dosage form(s) (capsules, creams, liquids, powder, tablets and others), and type of patient population (based on age and gender). In addition, it provides an in-depth analysis on the developers engaged in the development of antibiotic generics, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of approved generics). 
  • A detailed assessment of the overall market landscape of approved antibiotic brands, based on several relevant parameters, such as year of approval, region(s) of approval, type of antibiotic (based on chemical structure and drug class), mechanism of action (cell wall synthesis inhibition, DNA synthesis inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis inhibition and protein synthesis inhibition), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria(s) (gram negative  and gram positive), target bacterial strain(s), target diseases indication(s), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous and oral), dosage form(s) (capsules, creams, liquids, powder, tablets and others), type of patient population (based on age and gender) and type of innovation. In addition, it provides an in-depth analysis on the developers engaged in the development of antibiotic brands, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of approved brands). 
  • A detailed assessment of the overall market landscape of clinical-stage antibiotics, based on several relevant parameters, such as status of development (clinical and preclinical), stage of development, type of antibiotic (based on chemical structure and drug class), mechanism of action (cell membrane alteration, cell wall synthesis inhibition, FABI inhibition, fatty acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and others), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria(s) (gram negative and gram positive), target bacterial strain(s), target disease indication(s), therapeutic area(s) (genetic disorder, immunological disorder, infectious disease, oncological disorder, renal disorder and sexually transmitted disease), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral and others / unspecified), dosage form(s) (capsules, liquids, tablets and others / unspecified), dosage strength, dosage frequency, dosing period, type of patient population (based on age and gender) and special designation received (breakthrough therapy, fast track, orphan drug and qualified infectious disease product). In addition, it provides an in-depth analysis on the companies engaged in the development of clinical-stage antibiotics, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of clinical-stage antibiotics and number of preclinical-stage antibiotics).
  • Elaborate profiles of key players engaged in the development of antibiotics (shortlisted based on proprietary criterion), including a brief overview of the company, key executives, financial information (if available), product portfolio, recent developments and an informed future outlook. In addition, the chapter highlights the key strategies and key focus areas of the developers, along with expert opinion. 
  • A detailed analysis of partnerships inked between stakeholders engaged in this market, since 2017, based on several relevant parameters, such as year of partnership, type of partnership (acquisitions, commercialization agreements, distribution agreements, joint development agreements, licensing agreements, manufacturing agreements, product development agreements, product development and commercialization agreements, research and development agreements, technology utilization agreements and others), type of partner, company size, most active players (in terms of number of partnerships)., and regional distribution of partnership activity in this industry.
  • An analysis of completed and ongoing clinical trials related to antibiotics, based on several relevant parameters, such as trial registration year, trial status, trial phase, type of patient population (based on gender), key focus areas, type of sponsor, geography and most active industry and non-industry players (in terms of number of trials).
  • An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibiotics, based on several relevant parameters, such as type of KOL, qualification, type of organization, affiliated organization, geographical location of KOLs and target disease indication(s). In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
  • An elaborate discussion on key trends within the antibiotics industry providing insights on drug-pricing, outsourcing trends and impact of COVID-19 on the antibiotics market.
  • An insightful success protocol analysis of recently approved antibiotics, based on several relevant parameters, such as dosing frequency, drug efficacy, geographical reach, inter-class competition, intra-class competition, innovation feature, price, prevalence, route of administration, spectrum of activity, type of therapy and type of target bacteria.

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the global antibiotics market in the forecast period. We have provided an informed estimate on the likely evolution of the antibacterial drugs market in mid-term to long term for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of antibiotics classes (aminoglycosides, cephalosporins, fluoroquinolones, macrolides, penicillins, sulfonamides, tetracyclines and other classes), target disease indication (bacterial infections, skin infections, gastrointestinal infections, hematological infections,  nephrological infections, pulmonary infections, reproductive tract infections, respiratory tract infections, sexually transmitted diseases, urinary tract infections and  other bacterial infections), type of therapy (monotherapies and combination therapies), route of administration (intravenous and oral) and geography (North America, Europe, Asia-Pacific and Rest of the world). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com